170 related articles for article (PubMed ID: 3260986)
1. Systemic 1-methyl,4-phenyl,1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates.
Ghilardi MF; Chung E; Bodis-Wollner I; Dvorzniak M; Glover A; Onofrj M
Life Sci; 1988; 43(3):255-62. PubMed ID: 3260986
[TBL] [Abstract][Full Text] [Related]
2. Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model.
Ghilardi MF; Bodis-Wollner I; Onofrj MC; Marx MS; Glover AA
Brain; 1988 Feb; 111 ( Pt 1)():131-49. PubMed ID: 3259150
[TBL] [Abstract][Full Text] [Related]
3. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Falardeau P; Bouchard S; Bédard PJ; Boucher R; Di Paolo T
Eur J Pharmacol; 1988 May; 150(1-2):59-66. PubMed ID: 3261249
[TBL] [Abstract][Full Text] [Related]
4. Different sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: electrophysiological and biochemical evidence.
Harnois C; Marcotte G; Di Paolo T
Exp Eye Res; 1989 Oct; 49(4):543-52. PubMed ID: 2806423
[TBL] [Abstract][Full Text] [Related]
5. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.
Pérez-Otaño I; Oset C; Luquin MR; Herrero MT; Obeso JA; Del Río J
Neurosci Lett; 1994 Jul; 175(1-2):121-5. PubMed ID: 7970192
[TBL] [Abstract][Full Text] [Related]
6. Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl.
Saitoh T
J Neurol Sci; 1988 Feb; 83(2-3):161-6. PubMed ID: 3258627
[TBL] [Abstract][Full Text] [Related]
7. The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys.
Schultz W; Scarnati E; Sundström E; Tsutsumi T; Jonsson G
Exp Brain Res; 1986; 63(1):216-20. PubMed ID: 3488228
[TBL] [Abstract][Full Text] [Related]
8. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.
Schneider JS; Pope A; Simpson K; Taggart J; Smith MG; DiStefano L
Science; 1992 May; 256(5058):843-6. PubMed ID: 1350379
[TBL] [Abstract][Full Text] [Related]
9. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD
Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758
[TBL] [Abstract][Full Text] [Related]
10. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.
Zuddas A; Oberto G; Vaglini F; Fascetti F; Fornai F; Corsini GU
J Neurochem; 1992 Aug; 59(2):733-9. PubMed ID: 1629743
[TBL] [Abstract][Full Text] [Related]
11. Cerebral metabolism of parkinsonian primates 21 days after MPTP.
Schwartzman RJ; Alexander GM; Ferraro TN; Grothusen JR; Stahl SM
Exp Neurol; 1988 Dec; 102(3):307-13. PubMed ID: 3264247
[TBL] [Abstract][Full Text] [Related]
12. The visual system in Parkinson's disease.
Bodis-Wollner I; Tagliati M
Adv Neurol; 1993; 60():390-4. PubMed ID: 8420159
[No Abstract] [Full Text] [Related]
13. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost?
German DC; Dubach M; Askari S; Speciale SG; Bowden DM
Neuroscience; 1988 Jan; 24(1):161-74. PubMed ID: 3259295
[TBL] [Abstract][Full Text] [Related]
14. Spinal cord metabolism of the 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkey.
Schwartzman RJ; Alexander GM
Brain Res; 1985 Jul; 337(2):263-8. PubMed ID: 3875382
[TBL] [Abstract][Full Text] [Related]
15. Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys.
Eidelberg E; Brooks BA; Morgan WW; Walden JG; Kokemoor RH
Neuroscience; 1986 Aug; 18(4):817-22. PubMed ID: 3489906
[TBL] [Abstract][Full Text] [Related]
16. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.
Doudet DJ; Chan GL; Holden JE; McGeer EG; Aigner TA; Wyatt RJ; Ruth TJ
Synapse; 1998 Jul; 29(3):225-32. PubMed ID: 9635892
[TBL] [Abstract][Full Text] [Related]
17. Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys.
Guttman M; Yong VW; Kim SU; Calne DB; Martin WR; Adam MJ; Ruth TJ
Synapse; 1988; 2(5):469-73. PubMed ID: 3263709
[TBL] [Abstract][Full Text] [Related]
18. A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys.
Wolters EC; Kebabian JC; Guttman M; Mak E; Pate BD; Calne DB
Neurosci Lett; 1988 Dec; 95(1-3):257-61. PubMed ID: 3265771
[TBL] [Abstract][Full Text] [Related]
19. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP.
Rose S; Nomoto M; Kelly E; Kilpatrick G; Jenner P; Marsden CD
Neurosci Lett; 1989 Jul; 101(3):305-10. PubMed ID: 2505199
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.
Di Paolo T; Bédard P; Daigle M; Boucher R
Brain Res; 1986 Aug; 379(2):286-93. PubMed ID: 2427166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
